Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post Marketing Surveillance of Alesion® (Epinastine Hydrochloride) Tablet

NCT02238223 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02238223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02238223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post Marketing Surveillance of Alesion® (Epinastine Hydrochloride) Tablet
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Completed
Start date
April 30, 2004
Completion date
Not reported
Enrollment
2,001 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

rhinitis, allergic, perennial